Synlogic Inc Stock News

Oppenheimer upgraded shares of Synlogic (NASDAQ:SYBX) from a market perform rating to an outperform rating in a research report report published on Wednesday morning, Price Targets.com reports. The firm currently has $7.00 target price on the biotechnology companys stock. SYBX has been the subject of several other reports. HC Wainwright dropped their price objective on []

Equities analysts expect Synlogic, Inc. (NASDAQ:SYBX) to announce ($0.28) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Synlogics earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.33). Synlogic posted earnings of ($0.39) per share during the []

Synlogic Inc (NASDAQ:SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, stock fell 1.52% (As on Nov 26, 10:46:42 AM UTC-4, The post Synlogic Inc (NASDAQ:SYBX) Upgraded by Oppenheimer to Outperform appeared first on FXDailyReport.Com .

Synlogic (NASDAQ:SYBX) was upgraded by research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday, Analyst Ratings Network reports. The firm currently has a $7.00 target price on the biotechnology company’s stock. Oppenheimer’s price target points to a potential upside of […]

Synlogic (NASDAQ:SYBX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The firm currently has a $2.75 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 4.17% from the stock’s current price. According […]

Squarepoint Ops LLC reduced its holdings in Synlogic, Inc. (NASDAQ:SYBX) by 67.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,599 shares of the biotechnology companys stock after selling 85,714 shares during the quarter. Squarepoint Ops LLC owned approximately 0.08% of Synlogic []

Wall Street analysts forecast that Synlogic, Inc. (NASDAQ:SYBX) will report $330,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Synlogics earnings. The highest sales estimate is $400,000.00 and the lowest is $250,000.00. The firm is scheduled to report its next earnings results on Thursday, March []

CAMBRIDGE, Mass., Nov. 22, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of interim data from the company''s Phase 2 SynPheny-1 clinical trial showing that

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2021 Results - Earnings Call Transcript

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 0.00% and 233.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., Oct. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two post

CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the ap

CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricin

CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has